Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis.
Pollak TA., Kempton MJ., Iyegbe C., Vincent A., Irani SR., Coutinho E., Menassa DA., Jacobson L., de Haan L., Ruhrmann S., Sachs G., Riecher-Rössler A., Krebs M-O., Amminger P., Glenthøj B., Barrantes-Vidal N., van Os J., Rutten BPF., Bressan RA., van der Gaag M., Yolken R., Hotopf M., Valmaggia L., Stone J., David AS., EUGEI High-Risk Study None., McGuire P.
Serum neuronal autoantibodies, such as those to the NMDA receptor (NMDAR), are detectable in a subgroup of patients with psychotic disorders. It is not known if they are present before the onset of psychosis or whether they are associated with particular clinical features or outcomes. In a case-control study, sera from 254 subjects at clinical high risk (CHR) for psychosis and 116 healthy volunteers were tested for antibodies against multiple neuronal antigens implicated in CNS autoimmune disorders, using fixed and live cell-based assays (CBAs). Within the CHR group, the relationship between NMDAR antibodies and symptoms, cognitive function and clinical outcomes over 24 month follow-up was examined. CHR subjects were not more frequently seropositive for neuronal autoantibodies than controls (8.3% vs. 5.2%; OR = 1.50; 95% CI: 0.58-3.90). The NMDAR was the most common target antigen and NMDAR IgGs were more sensitively detected with live versus fixed CBAs (p